There is no FDA-approved Wegovy pill dosing chart because Wegovy is only approved as a once-weekly semaglutide injection for chronic weight management. Oral semaglutide exists under a different brand, Rybelsus, for type 2 diabetes. If you are considering semaglutide, dosing and eligibility should be reviewed by a licensed clinician 1, 2.
Wondering if semaglutide is right for you? Take the 3-min clinical quiz.
See if you qualify →| Wegovy treatment period | FDA-label dose | Route | Purpose of this step |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly | Subcutaneous injection | Starting dose used to help the body adjust; not a maintenance dose |
| Weeks 5–8 | 0.5 mg once weekly | Subcutaneous injection | Dose escalation step |
| Weeks 9–12 | 1 mg once weekly | Subcutaneous injection | Dose escalation step |
| Weeks 13–16 | 1.7 mg once weekly | Subcutaneous injection | Dose escalation step; may be used as a maintenance dose in some patients per label |
| Week 17 and after | 2.4 mg once weekly | Subcutaneous injection | Recommended maintenance dose per FDA label |
Is there a Wegovy pill dosing chart?
No. Wegovy has no pill dosing chart because Wegovy is not approved as a pill. The FDA label describes Wegovy as semaglutide injection for subcutaneous use, given once weekly for chronic weight management 1.
Why Wegovy is not available as a pill
Semaglutide is a peptide-like molecule, which means the digestive system can break it down before much of it gets into the bloodstream. Wegovy avoids that problem by using a subcutaneous injection, which places the medicine under the skin 1.
The clinical trials that supported Wegovy’s approval studied injectable semaglutide for weight management, not a Wegovy tablet. In the STEP 1 trial, adults without diabetes received once-weekly semaglutide 2.4 mg as an injection; nausea, diarrhea, vomiting, and constipation were common side effects, and individual results varied 4.
What people usually mean when they search for a Wegovy pill
Most people searching for a Wegovy pill are asking one of three things: whether Wegovy comes as a tablet, whether Rybelsus can be used like Wegovy, or whether semaglutide can be prescribed in another form. Those are different questions with different answers.
- Wegovy: semaglutide injection for chronic weight management 1.
- Rybelsus: oral semaglutide tablet approved for adults with type 2 diabetes 2.
- Ozempic: semaglutide injection approved for type 2 diabetes and certain cardiovascular and kidney risk indications in specific patients, not labeled as Wegovy 3.
- Compounded semaglutide: a clinician-prescribed compounded medication prepared by a state-licensed pharmacy when clinically appropriate; compounded drugs are not FDA-approved 8.
What is the FDA-approved Wegovy dosing schedule?
The FDA-approved Wegovy schedule starts at 0.25 mg once weekly for 4 weeks and increases in 4-week steps. The recommended maintenance dose is 2.4 mg once weekly, with 1.7 mg once weekly also listed as a maintenance option for some patients 1.
Standard once-weekly Wegovy dose escalation chart
Providers use the Wegovy label to understand the studied dose-escalation schedule. This is a reference chart, not a direction to start or change medication on your own.
| Step | Weeks | FDA-label Wegovy dose | Notes |
|---|---|---|---|
| Start | 1–4 | 0.25 mg once weekly | Initial dose used during treatment initiation |
| Escalation 1 | 5–8 | 0.5 mg once weekly | Dose increases after 4 weeks if clinically appropriate |
| Escalation 2 | 9–12 | 1 mg once weekly | Dose increases after 4 weeks if clinically appropriate |
| Escalation 3 | 13–16 | 1.7 mg once weekly | Dose increases after 4 weeks if clinically appropriate |
| Maintenance | 17+ | 2.4 mg once weekly | Recommended maintenance dose in the FDA label |
Why Wegovy doses are increased gradually
Dose escalation is used because GLP-1 receptor agonists can cause gastrointestinal side effects. In the Wegovy label, common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar in patients with type 2 diabetes, gas, gastroenteritis, and reflux 1.
What happens if a dose is not tolerated
The Wegovy label includes instructions for clinicians when a dose is not tolerated, including delaying escalation in some cases. It also lists warning symptoms that need prompt medical attention, including severe abdominal pain that may suggest pancreatitis or gallbladder disease 1.
How is oral semaglutide different from Wegovy?
Oral semaglutide is not the same product as Wegovy. Rybelsus is semaglutide in tablet form for adults with type 2 diabetes, while Wegovy is semaglutide injection for chronic weight management; the schedules, labels, and routes are different 1, 2.
Rybelsus versus Wegovy: brand, indication, and route
| Medication | Active ingredient | FDA-labeled use | Route | Typical label schedule |
|---|---|---|---|---|
| Wegovy | Semaglutide | Chronic weight management in eligible adults and adolescents; cardiovascular risk reduction in certain adults with established cardiovascular disease and obesity or overweight | Once-weekly subcutaneous injection | Starts at 0.25 mg once weekly, with stepwise escalation |
| Rybelsus | Semaglutide | Glycemic control in adults with type 2 diabetes | Oral tablet | Starts with a 3 mg daily initiation dose per label, then may increase by label schedule |
| Ozempic | Semaglutide | Type 2 diabetes and certain risk-reduction indications in specific patients | Once-weekly subcutaneous injection | Uses its own FDA-label schedule, not the Wegovy schedule |
| Compounded semaglutide | Semaglutide as prescribed and compounded | Not FDA-approved; may be prescribed after clinical evaluation when appropriate | Varies by the specific prescription and pharmacy formulation | Provider-guided; not interchangeable with a brand-label chart |
Why oral semaglutide is absorbed differently
Rybelsus includes an absorption enhancer called salcaprozate sodium, or SNAC, to help semaglutide cross the stomach lining. Even with that technology, oral semaglutide absorption is limited and is affected by how it is taken, which is why its label has specific administration instructions 2, 5.
Why Rybelsus dosing should not be treated as Wegovy dosing
Rybelsus dosing should not be converted into a Wegovy dosing chart. The two products were studied for different labeled uses, use different routes, and have different dose strengths and instructions 1, 2.
Can semaglutide be used for weight loss if it is not Wegovy?
Semaglutide has been studied for weight management as once-weekly injectable semaglutide 2.4 mg, but medication choice depends on the specific product, label, patient history, and clinician judgment. In STEP 1, injectable semaglutide was associated with weight loss versus placebo, while gastrointestinal side effects were also more common; individual results varied 4.
Ozempic, Wegovy, Rybelsus, and compounded semaglutide explained
Ozempic, Wegovy, and Rybelsus all contain semaglutide, a GLP-1 receptor agonist, but they are not the same medication. Compounded semaglutide is also not a generic Wegovy or generic Ozempic; it is a compounded prescription prepared by a pharmacy for a specific patient when a licensed clinician determines it is appropriate 1, 2, 3, 8.
FDA-approved medications versus compounded medications
FDA-approved medications have FDA-reviewed labeling, manufacturing, safety, and effectiveness data for their approved uses. Compounded drugs are not FDA-approved, and the FDA has warned patients about risks from unapproved semaglutide products, dosing errors, and products sold outside licensed medical care 8, 9.
When a licensed provider may discuss alternatives
A licensed provider may discuss different GLP-1 options based on health history, goals, access, side effects, and contraindications. This may include FDA-approved brand medications or compounded semaglutide through a state-licensed 503A pharmacy, when clinically appropriate and permitted.
3-min quiz
Considering semaglutide with clinical guidance?
Chia offers compounded semaglutide injection with an online health questionnaire, licensed-provider review, provider-guided dosing, and home delivery from US state-licensed 503A compounding pharmacies. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Semaglutide treatment at Chia: injections, clinician guidance, and microdosing
At Chia, compounded semaglutide is offered as an injection, with plans currently starting at $249/mo. Patients start with a 100% online visit, and a licensed US provider reviews eligibility before any prescription is written.
Chia’s semaglutide offering: compounded semaglutide injection
Chia offers compounded semaglutide injection, not a Wegovy pill and not oral semaglutide. When prescribed, medication is compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door.
| Chia option | Form | Current starting price | Best fit to discuss with a provider |
|---|---|---|---|
| Semaglutide | Injection | From $249/mo | Patients considering a GLP-1 plan with provider-guided dosing and microdosing plans when clinically appropriate |
| Tirzepatide | Tablets or injection | Tablets from $249/mo; injection from $299/mo | Patients comparing GLP-1/GIP options with a clinician; microdosing plans are available |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | From $309/mo | Patients discussing weight management plus energy-support goals with a provider |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | From $329/mo | Patients discussing weight management plus muscle-support goals with a provider |
How online evaluation and provider-guided dosing work
The Chia process starts with a short health questionnaire through the eligibility quiz. A licensed provider reviews medical history, medications, contraindications, and goals; dosing is provider-guided and adjusted over time through the patient portal.
Microdosing plans and why they still require clinician review
Chia offers semaglutide microdosing plans where clinically appropriate. Microdosing still requires the same medical review because GLP-1 medications can cause side effects and may not be appropriate for people with certain histories, including medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis concerns, gallbladder disease, or pregnancy considerations 1.
How Chia can be reached through the patient quiz or DoctorMCP
Patients can start directly through Chia’s online eligibility quiz. For prescription-delivery workflows, Chia can also be reached by AI agents through DoctorMCP at mcp.chia.health, with the same rule: a licensed clinical evaluation is required, and a prescription is never guaranteed.
Who may not be a good candidate for semaglutide?
Semaglutide is not right for everyone. The Wegovy label includes a boxed warning about thyroid C-cell tumors and says it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia syndrome type 2 1.
Medical history a clinician usually reviews
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 1.
- Past pancreatitis or symptoms that could suggest pancreatitis, such as severe persistent abdominal pain 1.
- Gallbladder disease, because gallbladder events have been reported with semaglutide treatment 1.
- Kidney problems, especially if vomiting or diarrhea could raise dehydration risk 1.
- Diabetes medications that can cause low blood sugar, such as insulin or sulfonylureas, because GLP-1 therapy may change hypoglycemia risk 1, 10.
Pregnancy, breastfeeding, and planned surgery considerations
The Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy because of the drug’s long half-life. The label also notes limited human data in pregnancy and lactation, so these situations should be reviewed directly with a clinician 1.
GLP-1 receptor agonists can delay gastric emptying. The American Society of Anesthesiologists has issued guidance for patients taking GLP-1 medications before procedures, and surgery plans should be discussed with the prescribing clinician and anesthesia team 11.
Side effects and warning symptoms to discuss with a provider
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, and bloating. Warning symptoms to discuss promptly include severe or persistent abdominal pain, repeated vomiting, signs of dehydration, allergic reaction symptoms, or mood changes 1.
What should patients compare before choosing a GLP-1 option?
Before choosing a GLP-1 option, compare route, labeled use, pharmacy source, follow-up, side effects, and cost. A licensed-provider review matters because the right choice depends on health history, medications, pregnancy plans, and tolerance.
Route: injection versus tablet
Some patients prefer a tablet, but route is not just a lifestyle choice. Wegovy is injection-only, Rybelsus is a tablet for type 2 diabetes, and Chia’s semaglutide offering is compounded injection; tirzepatide at Chia is offered as tablets or injection with microdosing plans available.
FDA approval status and labeled use
Wegovy, Ozempic, and Rybelsus each have FDA-approved labels for specific uses. Compounded semaglutide does not have FDA-approved labeling or FDA-evaluated outcomes data, so it should be considered through clinician review rather than by copying a brand dosing chart 1, 2, 3, 8.
Cost, access, pharmacy source, and clinical follow-up
Patients should know who is prescribing, where the medication is compounded or dispensed, how follow-up works, and what to do if side effects happen. Chia’s GLP-1-related protocols include Weight + Energy and Weight + Muscle, each requiring licensed-provider review before treatment.
Frequently asked questions
No. Wegovy is FDA-approved as a once-weekly semaglutide injection for chronic weight management. There is no FDA-approved Wegovy pill.
No. Rybelsus and Wegovy both contain semaglutide, but they are different products. Rybelsus is an oral tablet approved for type 2 diabetes. Wegovy is an injectable medication approved for chronic weight management.
A clinician may discuss oral semaglutide in some situations, but Rybelsus is not the same as Wegovy and should not be dosed using the Wegovy schedule. Any use outside a product’s FDA-approved label should be reviewed carefully with a licensed clinician.
The FDA-approved Wegovy label starts with 0.25 mg once weekly for the first 4 weeks, followed by gradual dose increases. This is label information, not personal dosing advice.
No. Compounded semaglutide is not FDA-approved and is not FDA-reviewed for safety, effectiveness, or manufacturing quality. It may be prescribed only when a licensed clinician determines it is clinically appropriate.
Chia offers compounded semaglutide injection through a 100% online process with licensed-provider review and home delivery from US state-licensed 503A compounding pharmacies when prescribed. A prescription is never guaranteed.
No. A Wegovy chart describes the FDA-approved brand-label schedule for Wegovy. Compounded semaglutide dosing must be set by the prescribing clinician and should not be copied from a brand chart.
3-min quiz
Start with a licensed clinical review
If you are evaluating semaglutide, Chia can help you review options through a 100% online visit. Our providers prescribe only when clinically appropriate, and eligibility is not guaranteed. You can also read more about compounded semaglutide injection before you begin.
References
- 1.Novo Nordisk Inc. Wegovy (semaglutide) injection, prescribing information. U.S. Food and Drug Administration, 2024.
- 2.Novo Nordisk Inc. Rybelsus (semaglutide) tablets, prescribing information. U.S. Food and Drug Administration, 2024.
- 3.Novo Nordisk Inc. Ozempic (semaglutide) injection, prescribing information. U.S. Food and Drug Administration, 2025.
- 4.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
- 5.Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 2018.
- 6.Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes: the STEP 2 randomized clinical trial. The Lancet, 2021.
- 7.Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 2021.
- 8.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, 2025.
- 9.U.S. Food and Drug Administration. Dosing errors associated with compounded injectable semaglutide products, 2024.
- 10.American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care, 2026.
- 11.American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists, 2023.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if semaglutide is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
